New hope for antipsychotic weight gain: dapagliflozin vs metformin showdown
NCT ID NCT07342764
First seen Jan 17, 2026 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This study compares two medications, dapagliflozin and metformin, to see which better controls weight gain caused by antipsychotic drugs. About 110 people aged 16 and older with conditions like schizophrenia will receive one of the drugs plus lifestyle advice. The goal is to find a safe, effective way to manage weight and improve overall health without stopping needed psychiatric treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SQU
Muscat, Oman
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.